Chrysos Corporation (ASX:C79): What Is Driving PhotonAssay Adoption in FY26?

Aditi Sarkar

12 November 2026 09:36 PM AEDT

Chrysos Corporation (ASX:C79): What Is Driving PhotonAssay Adoption in FY26?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Chrysos Corporation (ASX:C79) recorded AUD 88.1 million FY26 revenue.
FY26 EBITDA reached AUD 27.2 million, increasing 68%.
The EBITDA Margin improved to 31% in FY26.
Contracted PhotonAssay units reached 87 after four post-year agreements.

Chrysos Corporation Limited (ASX:C79) develops and supplies PhotonAssay technology, which provides mineral sample analysis for Mining companies and laboratories. Chrysos shares closed at AUD 6.65 on 12 November 2026. Its August FY26 results reported higher Revenue and EBITDA, alongside new instrument Lease agreements, with growth depending on deployments and the utilisation of equipment already operating for customers.

PhotonAssay Technology and Customer Applications

Chrysos combines analytical science, hardware and software to offer testing technology to the mining industry. PhotonAssay measures gold and other elements in sample material without using the conventional fire-assay process. The company’s commercial model includes contracted instruments deployed at customer or laboratory locations.

Chrysos Corporation (ASX:C79) serves mining and laboratory customers across multiple geographies. The useful distinction is between an agreement to deploy equipment, its physical installation, customer acceptance and the number of samples processed after commissioning. Each stage contributes different information about future commercial activity.

FY26 Instrument Contracts and Operational Developments

In its 11 August 2026 results, Chrysos reported 24 new lease agreements signed during FY26. Four further agreements signed after the reporting period lifted total contracted units to 87. Contracted systems are not necessarily all operating during the same period, so the headline number should not be treated as an installed operating fleet.

The company also described increasing global deployments and utilisation of PhotonAssay as factors behind FY26 financial performance. Such utilisation matters because sample processing drives activity after a unit is commissioned. Further customer contracts introduce installation, commissioning and service obligations that need to be completed before their full operational implications become visible.

FY26 Revenue, EBITDA and Mining Laboratory Context

Chrysos reported revenue of AUD 88.1 million for FY26, up 33% from AUD 66.1 million. EBITDA increased 68% to AUD 27.2 million from AUD 16.1 million, and the EBITDA margin rose to 31% from 24%. The difference between revenue growth and EBITDA growth reflects how the company’s reported operating Earnings changed, but EBITDA is not the same as statutory net profit or operating cash flow.

Chrysos Corporation (ASX:C79) supplies analysis technology rather than selling mined gold or copper. Its financial exposure is therefore related to customer sample volumes, laboratory capacity, equipment performance and the commercial terms of instrument deployments. Conditions in mining exploration and production can affect the Demand for assay work, even though Chrysos is not itself a Commodity producer.

Risks to Consider

The company faces equipment manufacturing, installation and maintenance risks. Delays between agreement signature and deployment can change the timing of revenue, while machine reliability and throughput influence the amount of testing work performed. Growth across international markets also involves logistics, customer support and regulatory considerations.

Customer concentration, contracts, Capital Expenditure and operating cash requirements should be considered separately from EBITDA. A higher number of contracted instruments does not guarantee the same pattern of earnings from every site, since utilisation rates can vary with the customer’s testing requirements.

What to Watch Next

Updates on instrument commissioning, deployed-unit counts, sample utilisation and customer agreements will help distinguish orders from operating activity. Subsequent financial reports can show the relationship between revenue, EBITDA, net profit and cash conversion as the installed fleet changes.

For Chrysos Corporation (ASX:C79), Research and Development in equipment design and automation is another operational area to track. Improvements need to translate into tested performance and commercially delivered equipment before they can be reflected in financial outcomes.

Key Insights

Chrysos reported higher FY26 revenue, EBITDA and EBITDA margin, together with additional PhotonAssay lease agreements. Its operating model connects contracted instruments to installation and sample utilisation. The next relevant evidence will come from deployments, throughput and financial reporting rather than assumptions about commodity prices. The disclosed growth rates are historical FY26 measures; they should not be treated as forecasts for future contracted instruments or customer testing demand.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.